Search
Innoviva Inc
INVAAdd to Watchlist
22.490USD
-0.150-0.66%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.68BMarket Cap
3.09P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Innoviva Inc is 8.00, ranking 55 out of 157 in the Pharmaceuticals industry. The average price target is 33.00, with a high of 45.00 and a low of 18.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
35.500
Target Price
+56.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Innoviva Inc
INVA
5
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Innoviva Inc's expected revenue for the next quarter?
Innoviva Inc's expected revenue is 110.98M.
What is Innoviva Inc's price target?
Analysts forecast that Innoviva Inc's price target is USD 33.00, with the highest forecast at USD 45.00 and the lowest forecast at USD 18.00.
How have Innoviva IncINVA's recent earnings per share performed?
The market expectation was USD 2.52, while Innoviva IncINVA's earnings per share (EPS) for the previous quarter was USD 2.19. EPS for the next quarter is expected at USD 0.44.
What is the analyst rating for Innoviva Inc?
Based on the ratings of Innoviva Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
